Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Samsung Medical Center
With
Seok Jin Kim
Consortium for Improving Survival of Lymphoma
Asia Lymphoma Study Group
Lymphoma Study Association
Dok Hyun Yoon
Arnaud Jaccard
Wee Joo Chng
Soon Thye Lim
Huangming Hong
Yong Park
Kian Meng Chang
Yoshinobu Maeda
Fumihiro Ishida
Dong-Yeop Shin
Jin Seok Kim
Seong Hyun Jeong
Deok-Hwan Yang
Jae-Cheol Jo
Gyeong-Won Lee
Chul Won Choi
Won-Sik Lee
Tsai-Yun Chen
Kiyeun Kim
Sin-Ho Jung
Tohru Murayama
Yasuhiro Oki
Ranjana Advani
Francesco d'Amore
Norbert Schmitz
Cheolwon Suh
Ritsuro Suzuki
Yok Lam Kwong
Tong-Yu Lin
This is a retrospective cohort study using anonymized information from patients with ENKTL. The following criteria are required: (1) Patients diagnosed with ENKTL, nasal type between January 1, 1995 and December 31, 2014; (2) Patients treated with non-anthracycline based therapy as an initial treatment. The pathology of initial diagnosis was reviewed by designated pathologists.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients diagnosed with ENKTL, nasal type
Patients diagnosed between January 1, 1995 and December 31, 2014
Patients treated with nonanthracycline-based therapy as the initial treatment after diagnosis
Nonanthracycline-based therapy includes the following treatments:
Radiotherapy including concurrent chemoradiation
You may not be if
Patients who had received anthracycline-based therapy, such as CHOP or CHOP-like regimens, as the initial treatment.
Patients who do not have pathology slides available for central review.